Enrico Martin

134 Chapter 6 54. Bredella MA, Torriani M, Hornicek F, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol . 2007;189:928–935. 55. Cardona S, Schwarzbach M, Hinz U, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol . 2003;29:536–541. 56. Chirindel A, Chaudhry M, Blakeley JO, et al. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization. J Nucl Med . 2015;56:379– 385. 57. Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): A long-term clinical study. Ann Oncol . 2008;19:390–394. 58. Benz MR, Czernin J, Dry SM, et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer . 2010;116:451–458. 59. Ferner RE, Lucas JD, O’Doherty MJ, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry . 2000;68:353–357. 60. Karabatsou K, Kiehl T-R, Wilson DM, et al. Potential role of 18fluorodeoxyglucose- positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery . 2009;65:A160-70. 61. Mautner VF, Brenner W, Funsterer C, et al. Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1. Anticancer Res . 2007;27:1819–1822. 62. Meany H, Dombi E, Reynolds J, et al. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer . 2013;60:59–64. 63. Hummel TR, Jessen WJ, Miller SJ, et al. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res . 2010;16:5048–5057. 64. Johansson G, Peng P-C, Huang P-Y, et al. Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. PLoS One . 2014;9:e115916. 65. Park S-J, Sawitzki B, Kluwe L, et al. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med . 2013;11:109. 66. Kaalep A, Sera T, Oyen W, et al. EANM/ EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems. Eur J Nucl Med Mol Imaging . 2018;45:412–422. 67. Brahmi M, Thiesse P, Ranchere D, et al. Diagnostic accuracy of PET/CT-guided percutaneous biopsies for malignant peripheral nerve sheath tumors in neurofibromatosis type 1 patients. PLoS One .;10 . Epub ahead of print 2015. DOI: 10.1371/journal.pone.0138386. 68. Gatidis S, Schmidt H, Gücke B, et al. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous 18 F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to 18 F-Fluorod. Invest Radiol . 2016;51:7–14.